Increased risk of rectal cancer after prostate radiation: a population-based study
- PMID: 15825064
- DOI: 10.1053/j.gastro.2004.12.038
Increased risk of rectal cancer after prostate radiation: a population-based study
Abstract
Background & aims: Radiation therapy for prostate cancer has been associated with an increased rate of pelvic malignancies, particularly bladder cancer. The association between radiation therapy and colorectal cancer has not been established.
Methods: We conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) registry data from 1973 through 1994. We focused on men with prostate cancer, but with no previous history of colorectal cancer, treated with either surgery or radiation who survived at least 5 years. We evaluated the effect of radiation on development of cancer for 3 sites: definitely irradiated sites (rectum), potentially irradiated sites (rectosigmoid, sigmoid, and cecum), and nonirradiated sites (the rest of the colon). Using a proportional hazards model, we evaluated the effect of radiation on development of colorectal cancer over time.
Results: A total of 30,552 men received radiation, and 55,263 underwent surgery only. Colorectal cancers developed in 1437 patients: 267 in irradiated sites, 686 in potentially irradiated sites, and 484 in nonirradiated sites. Radiation was independently associated with development of cancer over time in irradiated sites but not in the remainder of the colon. The adjusted hazards ratio for development of rectal cancer was 1.7 for the radiation group, compared with the surgery-only group (95% CI: 1.4-2.2).
Conclusions: We noted a significant increase in development of rectal cancer after radiation for prostate cancer. Radiation had no effect on development of cancer in the remainder of the colon, indicating that the effect is specific to directly irradiated tissue.
Comment in
-
Ionizing radiation and rectal cancer: victims of our own success.Gastroenterology. 2005 Apr;128(4):1114-7. doi: 10.1053/j.gastro.2005.02.036. Gastroenterology. 2005. PMID: 15825091 Review. No abstract available.
-
Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide.Gastroenterology. 2005 Aug;129(2):770-2. doi: 10.1016/j.gastro.2005.06.042. Gastroenterology. 2005. PMID: 16083743 No abstract available.
-
Prostate radiotherapy is associated with second cancers in many organs, not just the colorectum.Gastroenterology. 2005 Aug;129(2):773-4; author reply 774-5. doi: 10.1016/j.gastro.2005.06.045. Gastroenterology. 2005. PMID: 16083746 No abstract available.
Similar articles
-
Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis.Radiother Oncol. 2017 Apr;123(1):139-146. doi: 10.1016/j.radonc.2017.02.007. Epub 2017 Mar 9. Radiother Oncol. 2017. PMID: 28285840
-
Association of colorectal cancer and prostate cancer and impact of radiation therapy.Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1979-85. doi: 10.1158/1055-9965.EPI-09-0241. Epub 2009 Jun 16. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19531678
-
Increased risk of colon cancer after external radiation therapy for prostate cancer.Int J Cancer. 2008 Sep 1;123(5):1141-5. doi: 10.1002/ijc.23601. Int J Cancer. 2008. PMID: 18546265
-
Secondary Cancers After Radiation Therapy for Primary Prostate or Rectal Cancer.World J Surg. 2016 Apr;40(4):895-905. doi: 10.1007/s00268-015-3324-x. World J Surg. 2016. PMID: 26711638 Review.
-
Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis.Cancer Treat Rev. 2018 Jul;68:136-144. doi: 10.1016/j.ctrv.2018.05.008. Epub 2018 Jun 26. Cancer Treat Rev. 2018. PMID: 29957373 Review.
Cited by
-
Adoption of the OMOP CDM for Cancer Research using Real-world Data: Current Status and Opportunities.medRxiv [Preprint]. 2024 Aug 23:2024.08.23.24311950. doi: 10.1101/2024.08.23.24311950. medRxiv. 2024. PMID: 39228725 Free PMC article. Preprint.
-
Variation in patterns of second primary malignancies across U.S. race and ethnicity groups: a Surveillance, Epidemiology, and End Results (SEER) analysis.Cancer Causes Control. 2024 May;35(5):799-815. doi: 10.1007/s10552-023-01836-2. Epub 2024 Jan 11. Cancer Causes Control. 2024. PMID: 38206498
-
Incidence risk assessment of secondary cancer due to radiotherapy of women with rectal cancer using BEIR VII, EPA, and ICRP models.Rep Pract Oncol Radiother. 2023 Nov 16;28(5):571-581. doi: 10.5603/rpor.96870. eCollection 2023. Rep Pract Oncol Radiother. 2023. PMID: 38179292 Free PMC article.
-
Risk of secondary malignancy following radiation therapy for prostate cancer.Sci Rep. 2023 Nov 16;13(1):20083. doi: 10.1038/s41598-023-45856-z. Sci Rep. 2023. PMID: 37973983 Free PMC article.
-
Adenocarcinoma involving the urinary bladder.BMJ Case Rep. 2023 Jul 18;16(7):e252747. doi: 10.1136/bcr-2022-252747. BMJ Case Rep. 2023. PMID: 37463778 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
